MetLife Investment Advisors LLC grew its stake in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 12.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 70,353 shares of the company’s stock after acquiring an additional 7,600 shares during the quarter. MetLife Investment Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $1,711,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of TEVA. Wealthstreet Investment Advisors LLC purchased a new position in Teva Pharmaceutical Industries during the second quarter worth about $200,000. Greenleaf Trust purchased a new position in Teva Pharmaceutical Industries during the second quarter worth about $215,000. Court Place Advisors LLC purchased a new position in Teva Pharmaceutical Industries during the second quarter worth about $220,000. Miracle Mile Advisors LLC purchased a new position in Teva Pharmaceutical Industries during the second quarter worth about $227,000. Finally, Bristol Advisors LLC purchased a new position in Teva Pharmaceutical Industries during the second quarter worth about $231,000. Institutional investors and hedge funds own 64.51% of the company’s stock.

Shares of NYSE:TEVA opened at $23.86 on Tuesday. The stock has a market cap of $24.77 billion, a price-to-earnings ratio of 6.07, a PEG ratio of 3.04 and a beta of 0.70. The company has a quick ratio of 0.69, a current ratio of 1.03 and a debt-to-equity ratio of 1.86. Teva Pharmaceutical Industries Ltd has a 12 month low of $10.85 and a 12 month high of $25.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Thursday, August 2nd. The company reported $0.78 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.64 by $0.14. The company had revenue of $4.70 billion during the quarter, compared to analyst estimates of $4.75 billion. Teva Pharmaceutical Industries had a positive return on equity of 19.92% and a negative net margin of 47.98%. The firm’s revenue was down 17.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.02 earnings per share. research analysts predict that Teva Pharmaceutical Industries Ltd will post 2.67 EPS for the current fiscal year.

In other news, insider Deborah A. Griffin sold 2,376 shares of the stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $23.71, for a total value of $56,334.96. Following the completion of the sale, the insider now owns 2,376 shares in the company, valued at $56,334.96. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Sven Dethlefs bought 2,000 shares of the stock in a transaction dated Friday, August 3rd. The stock was bought at an average price of $21.92 per share, with a total value of $43,840.00. Following the purchase, the executive vice president now owns 6,445 shares of the company’s stock, valued at approximately $141,274.40. The disclosure for this purchase can be found here. In the last quarter, insiders sold 10,350 shares of company stock valued at $239,430. Insiders own 0.43% of the company’s stock.

Several equities analysts recently weighed in on the company. CIBC reiterated a “market perform” rating on shares of Teva Pharmaceutical Industries in a research report on Friday. Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, September 20th. Mizuho increased their target price on Teva Pharmaceutical Industries from $28.00 to $29.00 and gave the stock a “buy” rating in a research report on Monday, September 17th. Credit Suisse Group set a $26.00 target price on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Monday, September 17th. Finally, Wells Fargo & Co set a $23.00 target price on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Monday, September 17th. Seven research analysts have rated the stock with a sell rating, sixteen have given a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $21.11.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Further Reading: Risk Tolerance

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.